Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists

By Tobias Claff, Jing Yu, Véronique Blais, Nilkanth N Patel1, Charlotte Martin, Lijie Wu, Gye Won Han, Brian J. Holleran, Olivier Van Der Poorten, Kate L. White, Michael A. Hanson, Philippe Sarret, Louis Gendron, Vadim Cherezov2, Vsevolod Katritch, Steven Ballet, Zhi-Jie Liu, Christa E. Müller, Raymond C. Stevens

1. University of Southern California 2. Bridge Institute - University of Southern California

See also

No results found.

Published on

Type

journal-article

Author

Tobias Claff and Jing Yu and Véronique Blais and Nilkanth Patel and Charlotte Martin and Lijie Wu and Gye Won Han and Brian J. Holleran and Olivier Van der Poorten and Kate L. White and Michael A. Hanson and Philippe Sarret and Louis Gendron and Vadim Cherezov and Vsevolod Katritch and Steven Ballet and Zhi-Jie Liu and Christa E. Müller and Raymond C. Stevens

Citation

Claff, T. et al., 2019. Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists. Science Advances, 5(11), p.eaax9115. Available at: http://dx.doi.org/10.1126/sciadv.aax9115.

Abstract

Selective activation of the δ-opioid receptor (DOP) has great potential for the treatment of chronic pain, benefitting from ancillary anxiolytic and antidepressant-like effects. Moreover, DOP agonists show reduced adverse effects as compared to μ-opioid receptor (MOP) agonists that are in the spotlight of the current “opioid crisis.” Here, we report the first crystal structures of the DOP in an activated state, in complex with two relevant and structurally diverse agonists: the potent opioid agonist peptide KGCHM07 and the small-molecule agonist DPI-287 at 2.8 and 3.3 Å resolution, respectively. Our study identifies key determinants for agonist recognition, receptor activation, and DOP selectivity, revealing crucial differences between both agonist scaffolds. Our findings provide the first investigation into atomic-scale agonist binding at the DOP, supported by site-directed mutagenesis and pharmacological characterization. These structures will underpin the future structure-based development of DOP agonists for an improved pain treatment with fewer adverse effects.

DOI